At the beginning of the month, Myovant’s share price skyrocketed 55% after data from its Phase III HERO trial (NCT03085095) comparing relugolix with generic leuprolide were presented at the recent American Society of Clinical Oncology (ASCO) Virtual Meeting.
While experts acknowledged relugolix’s CV event reduction trend is in line with present data in gonadotropin-releasing hormone (GnRH) antagonists, most noted that even taken in totality, analyses thus far are only hypothesis-generating. Read more here.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
